Black Diamond Therapeutics (BDTX) EBITDA Margin (2025)
Black Diamond Therapeutics' (BDTX) quarterly EBITDA Margin came in at 77.9% in Q1 2025.
Black Diamond Therapeutics (BDTX) EBITDA Margin (2025) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 1 years of EBITDA Margin data on file, last reported at 77.9% in Q1 2025.
- Quarterly EBITDA Margin changed N/A year-over-year to 77.9% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 17.89% (changed N/A YoY) and the FY2025 annual result came in at 17.89%, changed N/A from the prior year.
- EBITDA Margin held at 77.9% in Q1 2025.
- In the past five years, EBITDA Margin ranged from a high of 77.9% in Q1 2025 to a low of 77.9% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 77.90% |